Table 3 Association with the number of alterations*
Variables | Median N of alterations (95% CI) (range) | P value (univariable) | t statistic (multivariable) | P value (multivariable) |
|---|---|---|---|---|
Overall | 1 (1–1) (0–26) | |||
Tumor type | ||||
Gastrointestinal | 2 (1–2) (0–26) | 0.031 | – | – |
Brain | 0 (0–0) (0–5) | < 0.001 | – | – |
Lung | 2 (2–3) (0–21) | < 0.001 | – | – |
Genomic alterations | ||||
MET | 4 (3–6) (1–21) | < 0.001 | 3.35 | 0.001 |
TP53 | 3 (3–3) (1–21) | < 0.001 | 6.86 | < 0.001 |
EGFR | 3 (3–4) (1–26) | < 0.001 | – | – |
PIK3CA | 5 (4–6) (1–26) | < 0.001 | 7.31 | < 0.001 |
BRAF | 5 (4–6) (1–26) | < 0.001 | 6.54 | < 0.001 |
KRAS | 4 (3–4) (1–26) | < 0.001 | 6.01 | < 0.001 |
MYC | 5 (3–6) (2–7) | < 0.001 | 2.70 | 0.007 |
Metastatic/recurrence at the time of blood draw | 2 (1–2) (0–26) | < 0.001 | – | – |
Metastatic sites | ||||
Lymph node | 2 (2–3) (0–21) | < 0.001 | 2.05 | 0.041 |
Bone | 2 (2–3) (0–26) | < 0.001 | – | – |
Liver | 2 (2–3) (0–26) | < 0.001 | – | – |
Lung | 2 (1–3) (0–19) | 0.010 | – | – |
Brain | 2 (1–3) (0–21) | < 0.001 | – | – |
Adrenal | 2 (2–4) (0–20) | < 0.001 | 2.06 | 0.040 |